AI Summary
Immune infertility refers to infertility caused by immune system abnormalities, including types such as positive antisperm antibodies, positive anti-endometrial antibodies, and positive antiphospholipid antibodies. In China, IVF (IVF/ICSI) is an effective treatment path for immune infertility, especially for patients with high-titer antisperm antibodies, recurrent miscarriage with immune factors, and those who have not conceived after standardized immunotherapy. Suitable candidates are those who have completed a comprehensive immunological evaluation, have a clear immune factor, and do not have an uncontrolled autoimmune disease; unsuitable candidates include those who have not completed systematic testing or have active autoimmune diseases (e.g., active systemic lupus erythematosus). The specific process includes: comprehensive immunological examination (1–2 weeks), registration at a reproductive center, personalized ovarian stimulation, egg retrieval, ICSI fertilization, embryo culture, embryo transfer, and luteal phase support, with a total cycle of about 2–3 months. Before treatment, key tests such as antisperm antibodies, antiphospholipid antibodies, antinuclear antibodies, and blocking antibodies must be completed, and the results determine whether combined immunomodulatory therapy (e.g., prednisone, hydroxychloroquine, IVIG) is needed. Success rates are influenced by multiple factors including age, ovarian reserve, type of immune factor, and embryo quality; individualized treatment at an experienced reproductive center is recommended.
Main text begins
1. IVF for Immune Infertility: Core Decision-Making Logic from a Doctor's Perspective
In reproductive clinics, when encountering patients with immune infertility, the doctor's first step is to distinguish the type of immune factor, antibody titer levels, and whether other causes of infertility are present. For patients with positive antisperm antibodies (AsAb), if the antibody titer is ≥1:32 and persists for more than 6 months, doctors typically recommend IVF directly rather than continuing attempts at natural conception or intrauterine insemination (IUI). The reason is that high-titer antisperm antibodies continuously agglutinate sperm in the female reproductive tract, inhibit the acrosome reaction, and hinder sperm-egg binding, whereas IVF technology—especially ICSI (intracytoplasmic sperm injection)—can directly bypass this immune barrier.
For patients with positive anti-endometrial antibodies (EmAb) or positive antiphospholipid antibodies (APA), the doctor will first assess whether there is a history of recurrent implantation failure or recurrent miscarriage. If there have been two or more failed embryo transfers or early miscarriages, immunomodulatory therapy should be combined with the IVF cycle rather than simply repeating the transfer.
2. Mechanism of Immune Infertility: Why IVF Can Bypass the Immune Barrier
The pathological mechanisms of immune infertility mainly involve the following categories. Understanding these mechanisms helps clarify the advantages of IVF treatment:
| Type of Immune Factor | Mechanism of Action | IVF Solution Path |
|---|---|---|
| Antisperm Antibody (AsAb) | Antibodies bind to sperm surface antigens, causing sperm agglutination, reduced motility, and blocked acrosome reaction | ICSI directly injects sperm into the egg cytoplasm, completely bypassing the antibody-affected environment |
| Anti-endometrial Antibody (EmAb) | Antibodies attack the endometrial epithelium, affecting the embryo implantation window | Combine immunosuppressive therapy (e.g., prednisone) before transfer to improve endometrial receptivity |
| Antiphospholipid Antibody (APA) | Activates vascular endothelium, leading to microthrombus formation and affecting placental blood flow | Use low molecular weight heparin + aspirin after transfer to improve placental perfusion |
| Antinuclear Antibody (ANA) | Associated with recurrent miscarriage and embryonic developmental arrest | Use immunomodulators such as hydroxychloroquine before transfer to reduce immune attack |
| Blocking Antibody Deficiency | Maternal inability to recognize the embryo as "self," leading to immune rejection | IVIG (intravenous immunoglobulin) or intralipid therapy |
From the mechanisms, it can be seen that IVF technology (especially ICSI) can physically bypass some immune barriers, but for antibodies involving systemic immune regulation (such as APA, ANA), combined drug therapy is required. This is why comprehensive immunological testing is an indispensable step before entering an IVF cycle.
3. Suitable and Unsuitable Candidates for IVF
Suitable Candidates
- Positive antisperm antibody with persistent titer ≥1:32, and no pregnancy after more than 6 cycles of natural conception or IUI.
- Positive anti-endometrial antibody, with recurrent implantation failure (≥2 failed transfers) or abnormal endometrial receptivity.
- Positive antiphospholipid antibody, with recurrent miscarriage (≥2 early miscarriages) or a prethrombotic state.
- Blocking antibody deficiency, with a history of embryonic arrest or biochemical pregnancy.
- Multifactorial immune abnormalities (e.g., concurrent AsAb and APA), with recommendation for IVF after consultation with a reproductive immunology department.
- Advanced age (≥38 years) combined with immune factors, with declining ovarian reserve, requiring prompt pursuit of pregnancy opportunities.
Unsuitable or Candidates Who Should Delay
- Incomplete comprehensive immunological testing (only single antibody tested)—unable to formulate a precise plan, and blind cycle entry yields poor results.
- Presence of uncontrolled active autoimmune disease, such as active systemic lupus erythematosus (SLE) or antiphospholipid syndrome (APS) with recent thrombosis—disease must first be controlled by a rheumatology department before considering IVF.
- Positive antibodies but no clinical infertility manifestations (e.g., incidental finding of AsAb positivity, natural conception attempted for less than 12 months)—direct IVF is not recommended; natural conception or IUI can be attempted first.
- Severe ovarian failure (AMH < 0.5 ng/mL) and immune factors are not the main issue—priority should be given to evaluating egg donation or fertility preservation options.
4. Actual IVF Process and Timeline for Immune Infertility
From the first immunological examination to embryo transfer, the complete cycle typically takes 2–3 months, divided into the following stages:
| Stage | Main Content | Time Required |
|---|---|---|
| 1. Comprehensive Immunological Assessment | Antisperm antibody, anti-endometrial antibody, antiphospholipid antibodies (ACA, β2-GP1), antinuclear antibody, blocking antibody, thyroid autoantibodies, NK cell activity, etc. | 1–2 weeks (some external tests take 7–10 days) |
| 2. Reproductive Center Registration + Protocol Development | Both partners complete basic tests (chromosomes, infectious diseases, semen analysis, AMH, antral follicle count); doctor formulates stimulation and immune intervention plan based on immune results | 1–2 weeks |
| 3. Ovarian Stimulation + Follicle Monitoring | Use gonadotropins (Gn) for controlled ovarian hyperstimulation; regular blood tests + ultrasound to monitor follicle development | 10–14 days |
| 4. Egg Retrieval + ICSI Fertilization | Ultrasound-guided egg retrieval; ICSI fertilization in the lab (ICSI routinely used to avoid antibody interference) | 1 day (rest 1–2 hours after retrieval) |
| 5. Embryo Culture + PGT (if needed) | Embryos cultured in vitro to day 3 (cleavage stage) or day 5–6 (blastocyst stage); PGT performed based on indications | 3–6 days |
| 6. Embryo Transfer + Luteal Phase Support | Embryo transfer in the mid-luteal phase or hormone replacement cycle; progesterone + immunomodulatory drugs used after transfer (per protocol) | 1 day (bed rest for 30 minutes after transfer) |
| 7. Pregnancy Test After Transfer | Blood test for β-hCG 12–14 days after transfer to confirm pregnancy | 12–14 days |
If immune pretreatment is required (e.g., using prednisone, hydroxychloroquine, or IVIG), medication usually needs to be started 4–6 weeks before ovarian stimulation begins, potentially extending the overall cycle to 3–4 months.
5. Key Test Indicator Interpretation: What Doctors Focus On
In the assessment of immune infertility, the following indicators are key focuses for reproductive doctors, each directly related to the choice of treatment plan:
- Antisperm Antibody (AsAb) — Titer ≥1:32 is positive; ICSI fertilization is recommended. If semen abnormalities (e.g., sperm agglutination) are also present, the indication for ICSI is stronger.
- Anti-endometrial Antibody (EmAb) — Positivity suggests possible impaired endometrial receptivity; prednisone 10–15 mg/day for 4–6 weeks is recommended before transfer.
- Antiphospholipid Antibodies (ACA, β2-GP1) — Moderate to high titer positivity with a history of thrombosis or miscarriage requires low molecular weight heparin + aspirin throughout pregnancy.
- Antinuclear Antibody (ANA) — Titer ≥1:80 with recurrent implantation failure; consider hydroxychloroquine 200–400 mg/day.
- Blocking Antibody (BA) — Negative (deficiency) is associated with embryo rejection; IVIG or intralipid therapy may be considered.
- NK Cell Activity (CD56+, CD16+) — Excessively high activity (>12%) suggests an immune attack tendency; can be modulated with IVIG or methylprednisolone.
- Thyroid Autoantibodies (TPOAb, TgAb) — Positivity is associated with miscarriage; TSH should be controlled below 2.5 mIU/L before transfer.
6. Most Easily Overlooked Details
In IVF treatment for immune infertility, the following details are often overlooked by patients but have a significant impact on outcomes:
- The male partner also needs immune testing — Male antisperm antibodies can cause sperm self-agglutination, affecting fertilization rates. If the male partner is AsAb positive, ICSI is necessary, and sperm washing + immunomagnetic bead selection may be required.
- Timing of immunomodulatory drugs — Drugs like prednisone and hydroxychloroquine need to be started in advance (usually 4–6 weeks), not on the day of transfer. The goal is to create an immune-tolerant environment before embryo transfer.
- Antibody titers can fluctuate — Infection, stress, and lack of sleep can cause transient increases in antibody titers. It is recommended to recheck antibody status before starting a cycle to avoid protocol deviations due to temporary fluctuations.
- Immunohistochemistry of endometrial biopsy — For patients with recurrent implantation failure, an endometrial biopsy in the mid-luteal phase is recommended to detect CD138+ plasma cells (chronic endometritis) and NK cell infiltration. This test may not be routinely available at all reproductive centers and requires proactive inquiry.
- Vitamin D levels — Vitamin D deficiency is linked to immune imbalance. It is recommended to maintain serum 25-OH-VD at ≥30 ng/mL to help improve immunomodulatory effects.
7. Most Common Pitfalls
Below are common cognitive misunderstandings and operational traps in clinical practice that require special attention:
Misconception 2: Believing that using ICSI means immune factors can be ignored. ICSI only solves immune interference at the sperm-egg binding stage. For post-implantation failures caused by antiphospholipid antibodies or antinuclear antibodies, ICSI alone cannot address them; systemic immunomodulation is needed.
Misconception 3: Blindly using IVIG after repeated implantation failure. IVIG is expensive (approximately 10,000–20,000 RMB per dose) and is not effective for all immune factors. Indications (such as blocking antibody deficiency or excessively high NK cell activity) should be confirmed through immunological testing before use to avoid ineffective expenditure.
Misconception 4: Ignoring the impact of thyroid autoantibodies. Even with normal TSH, the miscarriage risk is higher in TPOAb-positive individuals than in negative individuals. It is recommended to control TSH below 2.5 mIU/L before transfer, using levothyroxine if necessary.
8. Differences Across Age Groups
IVF strategies for immune infertility vary significantly across age groups, mainly in the following aspects:
| Age Group | Main Characteristics | Treatment Strategy Adjustments |
|---|---|---|
| < 35 years | Normal ovarian reserve, relatively single immune factor, good uterine receptivity | IUI can be attempted first (if not high-titer antibody); IVF cycles typically use conventional long or antagonist protocols; immune intervention can be moderately conservative |
| 35–37 years | Ovarian reserve begins to decline; immune factors may combine with age-related chromosomal risks | Direct ICSI is recommended; PGT-A (embryo chromosomal screening) may be considered to reduce miscarriage rates; immunomodulation used as indicated |
| 38–40 years | Reduced follicle count, increased embryo aneuploidy rate; immune factors and age factors overlap | Prioritize embryo accumulation strategy (multiple retrievals to accumulate blastocysts); immunotherapy focuses on improving endometrial receptivity; more thorough immune assessment needed before transfer |
| > 40 years | Significantly decreased ovarian function; embryo quality is the main issue | Fully assess the weight of immune factors in overall failure causes; if immune factors are not dominant, prioritize egg source issues; if immune factors are clear, individualize medication |
Advanced age itself is accompanied by changes in the immune system (e.g., increased inflammatory cytokine levels), making treatment more difficult for immune infertility patients over 40, requiring closer collaboration between the reproductive center and the immunology department.
9. Frequently Asked Questions
Q1: Is the success rate of IVF for immune infertility lower than for regular IVF?
With precise immune intervention, the IVF success rate for immune infertility patients is not significantly different from that of age-matched regular IVF patients. However, if immune factors are not identified or properly managed, the risks of repeated implantation failure and miscarriage increase significantly. Therefore, the key to success lies in the comprehensiveness of the immune assessment and the individualization of the intervention plan, not the disease itself.
Q2: What immune tests are needed, and how much do they cost?
A complete reproductive immunology test panel includes: antisperm antibody, anti-endometrial antibody, antiphospholipid antibodies (3 items), antinuclear antibody, blocking antibody, NK cell activity, thyroid autoantibodies, anti-ovarian antibody, etc. The cost is approximately 2,000–4,000 RMB (varies by region and hospital). Some tests (e.g., blocking antibody) need to be sent out, with a slightly longer waiting time.
Q3: Will immunotherapy affect the IVF cycle?
Immunomodulatory therapy (e.g., low-dose prednisone, hydroxychloroquine) is usually synchronized with ovarian stimulation and does not delay the cycle. However, IVIG or intralipid therapy needs to be infused 1–2 weeks before transfer and requires advance scheduling. All immune medications must be used under medical supervision and should not be stopped on your own.
Q4: Is immunotherapy needed after transfer?
If pregnancy is successful, patients with positive antiphospholipid antibodies or blocking antibody deficiency usually need to continue medication until 12–16 weeks of gestation, and some may need to continue into the second or third trimester. Antisperm antibodies and anti-endometrial antibodies generally do not require continued treatment after pregnancy. The specific time to stop medication is determined jointly by the immunology and obstetrics departments.
Q5: What if the male partner has antisperm antibodies and the female partner does not?
Male AsAb positivity can reduce sperm quality. It is recommended to use sperm immunomagnetic bead separation (MACS) combined with ICSI during the IVF cycle to remove antibody-bound sperm and select functionally normal sperm for injection. Additionally, the male partner can take oral L-carnitine, CoQ10, etc., to improve sperm quality, but results vary individually.
10. Doctor's Recommendation: Treatment Path Summary
① Complete comprehensive immunological testing (both partners) → ② Bring reports to the reproductive center + reproductive immunology department for joint evaluation → ③ Develop an individualized ovarian stimulation and immune intervention plan based on antibody type and titer → ④ Perform ICSI fertilization (routinely recommended) → ⑤ Confirm endometrial receptivity and immune status before transfer → ⑥ Use medication as per protocol after transfer and regularly monitor antibody titers and pregnancy indicators.
Treatment for immune infertility cannot be solved by a single technology; it requires multidisciplinary collaboration among reproductive medicine, immunology, and pharmacy. In China, large reproductive centers (such as Peking University Third Hospital, Shanghai Ninth People's Hospital, CITIC Xiangya, West China Second University Hospital, etc.) have reproductive immunology specialties or regular consultation channels with rheumatology and immunology departments; it is recommended to prioritize such centers.
Finally, it must be emphasized: IVF for immune infertility is not a one-size-fits-all solution, but a systematic project requiring precise diagnosis, individualized medication, and full-cycle monitoring. Patients should plan their time well (allow at least 3–4 months) and avoid rushing into transfer without proper immune assessment, which could lead to repeated failure.
End: Doctor's recommendation (integrated above) + Risk reminder
Immune Infertility IVF Antisperm Antibody Anti-endometrial Antibody Antiphospholipid Antibody ICSI Reproductive Immunology IVF in China Assisted Reproduction Knowledge Base
Comments (0)